Aetna does cover hormone replacement therapy in most cases: standard FDA-approved estrogen, progesterone, and testosterone products are on the formulary and typically run through the pharmacy benefit without prior authorization. The exceptions matter, though. Aetna does not cover compounded bioidentical hormones, treats most implantable hormone pellets as experimental, imposes documentation requirements on testosterone prescriptions, and, as of the 2026 plan year, no longer covers hormones prescribed for gender transition on federal employee plans.
Standard HRT Drugs on the Aetna Formulary
Aetna’s 2025 Standard Plan Pharmacy Drug Guide lists a wide range of menopause and hormone products. Estrogen coverage includes generic estradiol in tablet, patch, and vaginal cream form, estradiol-norethindrone combinations, and brand products such as Climara Pro, CombiPatch, Duavee, Imvexxy, Premphase, Prempro, and Vagifem. Progesterone options include generic micronized progesterone, medroxyprogesterone, and brand products like Crinone and Endometrin. Testosterone products on the formulary include generic testosterone gel, testosterone solution, and brand options Natesto and Xyosted.1Aetna. 2025 Drug Guide – Aetna Standard Plan
According to one employer-plan summary, testosterone and estrogen therapies filled through the prescription drug benefit typically do not require precertification.2Truist Benefits. Aetna Gender Affirming Care Your actual cost depends on the plan’s tier design. Aetna uses tiers such as Preferred Generic, Preferred Brand, and Non-Preferred, with generics carrying the lowest cost-sharing.3Formulary Navigator. 2025 Aetna Health Exchange Plan Drug Guide Check your own plan documents or your Aetna.com account for the copay that applies to a specific drug.
What Aetna Will Not Cover
Implantable Hormone Pellets
Aetna considers implantable estradiol pellets experimental, investigational, and unproven. Clinical Policy Bulletin 0345 says these pellets produce “unpredictable and fluctuating serum concentrations of estrogen” and that no FDA-approved, commercially available estradiol pellet formulation exists in the United States. The policy cites FDA advisory committee concerns about bleeding, infection, difficulty reversing the dose, and overdosage risk.4Aetna. Implantable Hormone Pellets – Clinical Policy Bulletin 0345 Implantable progestin and progesterone pellets are classified the same way.
Testosterone pellets (Testopel) are the one exception, and only for a narrow set of conditions: delayed male puberty, primary or hypogonadotropic hypogonadism with documented low testosterone, and gender dysphoria meeting specific criteria.4Aetna. Implantable Hormone Pellets – Clinical Policy Bulletin 0345 They are not covered for menopause symptoms, age-related hypogonadism, or pain management in women.
Compounded and Bioidentical Hormones
Aetna classifies compounded bioidentical hormones as experimental, investigational, and unproven. The clinical policy bulletin on the subject cites an American College of Obstetricians and Gynecologists committee opinion that there is “no scientific evidence to support claims of increased safety or effectiveness” for individually compounded estrogen or progesterone regimens. The policy also notes an FDA analysis in which 34% of sampled compounded products failed standard quality tests.5Aetna. Bioidentical Hormones – Clinical Policy Bulletin 0388 Aetna’s Medicaid policy is just as direct: compounded “hormone therapy compound for menopause or for androgen decline due to aging (e.g., testosterone, estrogen, progestin, bioidentical hormone)” is explicitly excluded.6Aetna Better Health. Compounded Drug Products Policy
Testosterone: Documentation Aetna Requires
Testosterone carries the most detailed prior authorization rules of any HRT category. For testosterone cypionate injections, Aetna requires at least two confirmed low morning serum testosterone levels, drawn on separate days, before approving therapy for hypogonadism.7Aetna. Testosterone Cypionate Injection – Clinical Policy Bulletin 1014 The precertification form sets the thresholds: two total fasting serum testosterone levels below 300 ng/dL (or below the lab’s reference range), drawn between 7:00 and 10:00 a.m. on different days. For borderline results between 300 and 400 ng/dL, two low free or bioavailable testosterone values below the lab’s reference range are required.8Aetna. Precertification Request for Prescription Drugs
Aetna considers testosterone experimental and not covered for age-related or “late-onset” hypogonadism, female sexual dysfunction, male menopause, cognitive decline in aging men, and performance enhancement.7Aetna. Testosterone Cypionate Injection – Clinical Policy Bulletin 1014 Whether a request is coded as clinically documented hypogonadism or as age-related decline is often what determines approval.
Hormones for Gender Transition
Commercial Plans
On commercial plans, Aetna covers gender-affirming hormone therapy when specific criteria are met. For testosterone cypionate, adults need a documented diagnosis of gender dysphoria, the ability to provide informed consent, reasonably controlled comorbid conditions, education about side effects, and documented counseling on fertility preservation.7Aetna. Testosterone Cypionate Injection – Clinical Policy Bulletin 1014 Puberty-suppressing GnRH agonists such as leuprolide and histrelin require precertification and must meet World Professional Association for Transgender Health criteria, with a specialist in transgender youth care prescribing.9Aetna. Gonadotropin-Releasing Hormone Analogs and Antagonists – Clinical Policy Bulletin 0501 Coverage specifics can also vary by the employer’s plan selection.10Aetna. Gender Affirming Surgery – Clinical Policy Bulletin 0615
Federal Employee Plans
Federal Employees Health Benefits plans changed sharply for the 2026 plan year. Following executive orders issued in January 2025, the Office of Personnel Management directed all FEHB carriers, including Aetna, to eliminate coverage for “chemical and surgical modification of an individual’s sex traits,” including gender transition services, for enrollees of all ages.11Government Executive. Coverage for Gender-Affirming Care Will Be Eliminated in FEHB Plans for 2026
Aetna’s federal plan page confirms that hormone therapy for gender transition is no longer covered except through a narrow continuation-of-care exception. To qualify, you must have stayed in the same Aetna plan from 2025, had preauthorization approved before January 1, 2026, and had an initial prescription fill before that date. People under 19 are not eligible for any exceptions.12Aetna Federal Plans. Gender Affirming Care Counseling for gender dysphoria remains covered.13OPM. FEHB Carrier Letter 2025-01b
The exclusion applies only to hormones prescribed for gender transition. Hormones prescribed for other medical reasons, including cancer treatment, endometriosis, or menopause, are not affected.11Government Executive. Coverage for Gender-Affirming Care Will Be Eliminated in FEHB Plans for 2026
Medicaid
Aetna Better Health, the insurer’s Medicaid managed-care arm, sets its own gender-affirming care policies state by state, so coverage, prior authorization rules, and age minimums depend on where you live.14Aetna Better Health. Gender-Affirming Care Services – Maryland Policy
Non-Hormonal Options for Menopause Symptoms
If hormone therapy is off the table, Aetna plans also cover non-hormonal prescription treatments for menopause symptoms, including low-dose antidepressants, gabapentin, and clonidine.15Adobe Benefits. Aetna Medical Plan Documentation Fezolinetant (Veozah), a newer non-hormonal drug FDA-approved for moderate to severe hot flashes, is covered under Aetna Better Health Medicaid plans but requires prior authorization and documented failure of, intolerance to, or contraindication to three formulary alternatives first.16Aetna Better Health. Veozah Coverage Policy Approvals run 12 months with a quantity limit of 30 tablets per 30 days.
HRT Is Not Preventive Care
Hormone replacement therapy is not classified as preventive care under the ACA or Aetna’s own preventive-services guidelines. Aetna’s preventive coverage list for women includes mammography, cervical cancer screening, BRCA counseling, and osteoporosis screening for women over 60, but no menopause treatments.17Aetna. Preventive Care Coverage HRT is subject to the usual deductible, copay, and coinsurance under your plan. Bone density screening for eligible women is the only menopause-adjacent service that qualifies as no-cost preventive care.18Healthcare.gov. Preventive Care Benefits for Women
If Aetna Denies Your HRT Claim
A denial for a prescription, a specific formulation, or a particular indication can be appealed. The internal appeal is the first step and must be filed within 180 days of the denial notice. You can call the number on your ID card, submit a written complaint and appeal form, or have your doctor start the process. Decision timelines depend on whether your plan uses one or two levels of appeal and whether the claim is pre-service or post-service. Urgent appeals, where delay could affect your health, can produce a decision within 72 hours (or 36 hours on two-level plans).19Aetna. Appeal a Denied Claim
For prior authorization denials specifically, your prescriber can request a peer-to-peer review with an Aetna clinician to walk through the clinical evidence for the treatment.20Aetna. Dispute Process If internal appeals fail, you can request an external review by an independent third party, a right guaranteed under the ACA for most plans, and your state insurance department can also help with disputes.21Aetna. Complaints, Grievances and Appeals